245 hasil
Menampilkan 1–20 · 0,14 detik · RSS
Journal of Immunotherapy and Precision Oncology
Scopus
ISSN 2590-017X · Innovative Healthcare Institute · 245 artikel di indeks
-
Artikel Jurnal Teks lengkap
Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer
Prostate cancer is the most common non-cutaneous malignancy affecting men in the United States, with the incidence of metastatic disease rising. Despite modern androgen deprivation therapy (ADT), nearly all cases of metastatic prostate cancer develop castration resistance. Informed by successes in…
-
Artikel Jurnal Teks lengkap
Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond
The class II major histocompatibility complex transactivator (CIITA) is a non–DNA-binding master regulator of major histocompatibility complex class II (MHC-II) gene expression, essential for antigen presentation and adaptive immunity. Functioning as a scaffold, CIITA recruits chromatin remodelers…
-
Artikel Jurnal Teks lengkap
Abstracts Presented at the 2026 Precision Oncology Saudi Summit: February 12–14, 2026, Madinah, Saudi Arabia
-
Artikel Jurnal Teks lengkap
Abstracts for the 2026 Immunotherapy and Precision Oncology Forum: April 11, 2026, Cincinnati, OH, USA
-
Artikel Jurnal Teks lengkap
SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review
SMARCA4 is an ATPase subunit in the switch/sucrose non-fermentable complex (SWI/SNF), a chromatin-remodeling complex. SMARCA4 provides energy for the SWI/SNF complex to regulate gene expression through chromatin structural rearrangement and transcription regulation. In SMARCA4-deficient cancers…
-
Artikel Jurnal Teks lengkap
The Double-Edged Role of Social Media in Modern Healthcare: Awareness, Impact, and Misinformation
Social media platforms influence healthcare. Social media engagement creates opportunities for health education, networking, patient empowerment, and public health initiatives. However, misinformation is common and circulates alongside accurate information. Additional concerns with online…
-
Artikel Jurnal Teks lengkap
Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical Advances, and Future Directions
A rapidly advancing class of engineered immunoglobulins, known as bispecific antibodies (bsAbs), that bind two distinct antigens offers new approaches for tumor targeting and immune modulation. BsAbs function as immune cell engagers, immune checkpoint modulators, or signaling pathway inhibitors…
-
Artikel Jurnal Teks lengkap
Impact of Germline BRCA Status on Pathologic Complete Response (pCR) and Outcomes in Early TNBC Treated with Pembrolizumab-Based Neoadjuvant Chemotherapy (KEYNOTE-522 Regimen): A Real-World Study
Introduction Pembrolizumab-based neoadjuvant chemoimmunotherapy following the KEYNOTE-522 regimen (NCT03036488) is a standard treatment approach for stage II and III triple-negative breast cancer (TNBC). Real-world evidence on the impact of germline BRCA status on pathologic complete response (pCR)…
-
Artikel Jurnal Teks lengkap
Beyond Visibility: Social Media, Trust, and Responsibility in Oncology
-
Artikel Jurnal Teks lengkap
Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies
Background High-grade gliomas are associated with dismal outcomes and have devastating neurologic sequelae. Standard-of-care surgery, radiation, and temozolomide yield a median survival of 14–16 months in patients with glioblastoma (GBM). Methods We report four patients with high-grade glioma (two…
-
Artikel Jurnal Teks lengkap
Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer
Introduction Prognosis of metastatic pancreatic cancer remains poor. KRAS mutations are common in pancreatic cancer and are an attractive therapeutic target. Based on a next-generation mechanistic dynamic model, we hypothesized that a combination of type I½ RAF inhibitor (vemurafenib) and type II…
-
Artikel Jurnal Teks lengkap
Prevalence of Molecular Mutations in Non–Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion
Over the past decade, the discovery of immunotherapy and targeted therapy has set new standards for the management of advanced non–small cell lung cancer (NSCLC). This study aims to investigate the prevalence of ALK, EGFR, KRAS, ROS1, MET, BRAF, and HER2 mutations in patients with NSCLC within the…
-
Artikel Jurnal Teks lengkap
Exceptional Response to Immunotherapy-based Treatment in Compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report
Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non–small cell lung cancer (NSCLC) with limited treatment options and poor prognosis. EGFR mutations generally respond to tyrosine kinase inhibitors (TKIs)-based targeted therapy but are typically associated with resistance…
-
Artikel Jurnal Teks lengkap
Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment
The combination of targeted therapies and immunotherapies for advanced and metastatic sarcomas has been proposed owing to the enhanced effect of antiangiogenic therapies on the tumor microenvironment. We found eight studies published to date assessing the effectiveness of combined multitargeted…
-
Artikel Jurnal Teks lengkap
Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials
Introduction Patients with advanced solid tumors may be considered for early phase clinical trials investigating the safety, tolerability, and dosing of experimental therapies. Optimizing participant selection is critical to maximize clinical benefit and meet trial endpoints with fewer…
-
Artikel Jurnal Teks lengkap
More Than Medicine: The Hope, Hurdles, and Hidden Costs of IgG Therapy
-
Artikel Jurnal Teks lengkap
Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration
Introduction Enadenotucirev (EnAd) and successor transgene-armed Tumor-Specific Immuno-Gene (T-SIGn) vectors are replication-competent, blood-stable viral vectors that traffic to tumor sites following intravenous (IV) administration. Following initial proof of mechanism for this immunotherapy…